Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pentoxifylline: a new agent for intermittent claudication.

D E Baker, R K Campbell

    Drug Intelligence & Clinical Pharmacy
    |May 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms.

    Clinical pharmacology and therapeutics·2016
    Same author

    Effect of test environment on expression of clines and on delimitation of seed zones in Douglas-fir.

    TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·2013
    Same author

    Sex pheromone of hickory shuckwormCydia caryana Development of an effective field Lure.

    Journal of chemical ecology·2013
    Same author

    Monitoring and assessment of soil and forage molybdenum near an atmospheric source.

    Environmental monitoring and assessment·2013
    Same author

    Force spectroscopy of hepatocytic extracellular matrix components.

    Ultramicroscopy·2009
    Same author

    Fine-scale quantification of HCG beta gene transcription in human trophoblastic and non-malignant non-trophoblastic tissues.

    Molecular human reproduction·2007
    Same journal

    Profile of prescription medication in a pediatric population.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    SI units in drug therapeutics.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Physicians' review of significant interventions by clinical pharmacists in inpatient care.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Possible interaction of ranitidine with phenytoin.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Famotidine-associated mental confusion in elderly patients.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Intravenous self-administration of elemental mercury: efficacy of dimercaprol therapy.

    Drug intelligence & clinical pharmacy·1988
    See all related articles

    Pentoxifylline improves symptoms and function for patients with intermittent claudication due to chronic arterial disease. This medication enhances red blood cell flexibility, offering a viable treatment option.

    Area of Science:

    • Pharmacology
    • Vascular Medicine
    • Hematology

    Background:

    • Pentoxifylline is FDA-approved for treating intermittent claudication in chronic occlusive arterial disease.
    • It serves as an adjunct therapy, not a replacement for surgical interventions.
    • The drug aims to improve limb function and alleviate disease symptoms.

    Purpose of the Study:

    • To summarize the efficacy and mechanism of action of pentoxifylline in treating peripheral arterial disease.
    • To highlight its benefits over placebo and alternative therapies.
    • To discuss its safety profile and dosage considerations.

    Main Methods:

    • Review of existing clinical studies and pharmacological data.
    • Analysis of pentoxifylline's effects on erythrocyte properties.

    Related Experiment Videos

  • Comparison of efficacy against placebo and nylidrin.

    • Main Results:

    • Pentoxifylline enhances erythrocyte flexibility by influencing adenosine triphosphate (ATP) concentrations and protein phosphorylation.
    • Clinical trials demonstrate significantly greater efficacy compared to placebo or nylidrin.
    • Adverse effects are predominantly gastrointestinal and manageable with controlled-release formulations.

    Conclusions:

    • Pentoxifylline is an effective treatment for improving symptoms and function in patients with intermittent claudication.
    • Its mechanism involves enhancing red blood cell deformability.
    • Controlled-release forms minimize adverse reactions, making it a valuable therapeutic option.